Glucagon-Like Peptide-1 (GLP-1) Suppression of Alpha Cell Secretion in Type 2 Diabetes Mellitus (T2DM)
Information source: University Hospital, Gentofte, Copenhagen
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Hyperglycemia; Hyperglucagonemia; Glucose Intolerance
Intervention: GLP-1 infusion (Other)
Phase: N/A
Status: Completed
Sponsored by: University Hospital, Gentofte, Copenhagen
Summary
The incretin hormone glucagon-like peptide-1 (GLP-1) has known insulinotrophic and
glucagonostatic properties. However, inpatients with type 2 diabetes mellitus (T2DM)it is
shown, that the beta cell sensitivity towards GLP-1 is decreased, when comparing to healthy
controls. Further, these patients have decreased GLP-1 response to a meal.
The aim of this study is to elucidate if the diabetic hyperglucagonemia, seen in these
patients both during fasting and in a postprandial condition, is coursed by a decreased
sensitivity to GLP-1 in the diabetic alpha cell.
Ten T2DM patients and ten matched healthy control subjects will be examined on two separate
days. Day 1: increasing GLP-1 infusions and Day 2: saline. During both days plasma glucose
(PG) will be clamped at fasting level (FPG).
Patients with T2DM will be submitted til a Day 3, here PG will be normalized over-night by
an adjustable insulin infusion, on the following day the GLP-1 infusion of Day 1 will be
repeated.
The hypothesis is that these patients have decreased alpha cell sensitivity to GLP-1 as is
the case with the beta cell sensitivity. This decreased sensitivity, the investigators
speculate, contributes the defect suppression og glucagon and thereby to the increased PG
levels seen in T2DM. Further the investigators will elucidate if this sensitivity can be
increased by normalizing the diabetic PG to a normal FPG level.
Clinical Details
Official title: GLP-1 Suppression of Alpha Cell Secretion in T2DM
Study design: Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject)
Primary outcome: glucagon suppression
Eligibility
Minimum age: 18 Years.
Maximum age: 70 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- T2DM according to WHO criteria
- Written consent
- Age > 18 years
Exclusion Criteria:
- Kidney or hepatic disease
- Treatment with insulin or glitazone
Locations and Contacts
Additional Information
Starting date: October 2006
Last updated: March 17, 2009
|
